KEROS THERAPEUTICS INC

Insider buying signals renewed optimism for KEROS; owner Seth Alpna’s new RSUs and options, amid a broader insider surge, suggest confidence in the company’s pipeline and undervalued stock.

Alpna’s 2026 sell of 2,625 KEROS shares amid 388% buzz shows insider liquidity moves; monitor future trades and clinical updates for potential volatility and dilution risk.

Insider buying by Keros Therapeutics’ director signals confidence amid volatility, offering investors insight into potential rebound prospects.

Insider sales at Keros Therapeutics are routine “sell‑to‑cover” tax‑withholding moves, not a sign of panic, leaving the company’s biotech prospects intact.